Catálogo de publicaciones - revistas

<jats:title>Summary</jats:title><jats:sec><jats:title>Background and Aims</jats:title><jats:p>Pruritus frequently reduces quality of life (<jats:styled-content style="fixed-case">QOL</jats:styled-content>) in patients with senile xerosis. This study investigated the moisturizing and antipruritic effects of a topical emollient containing a diethylene glycol/dilinoleic acid copolymer (D/<jats:styled-content style="fixed-case">DC</jats:styled-content>) in patients with pruritic senile xerosis.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>This single‐blind study involved 50 subjects, aged 50‐75 years. Patients were randomized to self‐applied treatment of the lower legs with 10% (n = 20) or 20% (n = 20) D/<jats:styled-content style="fixed-case">DC</jats:styled-content>‐containing cream, white petrolatum (n = 5), or no treatment (n = 5) thrice daily for four weeks. Clinical scores of skin dryness and scratch marks, skin conductance, and Skindex‐16 were evaluated before and after treatment. The degree of pruritus was evaluated by visual analog scale (<jats:styled-content style="fixed-case">VAS</jats:styled-content>) score once a week.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Patients treated with 10% and 20% D/<jats:styled-content style="fixed-case">DC</jats:styled-content> showed significant improvements in skin dryness and scratch mark scores, as well as increased skin conductance, compared with the untreated group, whereas white petrolatum treatment improved only skin dryness scores. Moreover, patients treated with 20% D/<jats:styled-content style="fixed-case">DC</jats:styled-content> showed significant improvements in skin dryness scores and skin conductance compared with white petrolatum treatment. The <jats:styled-content style="fixed-case">VAS</jats:styled-content> scores in the D/<jats:styled-content style="fixed-case">DC</jats:styled-content>‐treated and white petrolatum‐treated groups were significantly lower than in the untreated group, being particularly lower after one week of treatment with 20% D/<jats:styled-content style="fixed-case">DC</jats:styled-content>.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Topical application of an emollient containing D/<jats:styled-content style="fixed-case">DC</jats:styled-content> is effective in improving skin dryness and pruritus in patients with senile xerosis.</jats:p></jats:sec>

<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Melasma is a disorder of melanogenesis among humans causing localized, chronic acquired hypermelanosis of the skin requiring a combination of treatments. Related studies have shown probiotics contribute distinct advantages for skin disorders possibly including melasma because of its anti‐inflammatory activities, anti‐oxidation properties, ultraviolet protection, and tyrosinase activity inhibition.</jats:p></jats:sec><jats:sec><jats:title>Aims</jats:title><jats:p>The study aimed to investigate the effects of synbiotics supplement on improving melasma (evaluated from mMASI score).</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>This research comprised an experimental study employing a prospective, double‐blind, randomized controlled trial among 57 Thai participants divided in 2 groups (29 for the experimental and 28 for the placebo groups). The participants were aged 30‐50 years old, had Fitzpatrick skin type III–VI, with facial melasma on both sides of the face and attending Mae Fah Luang University Hospital, Bangkok from January‐December 2019. Participants were randomly treated with oral synbiotics or placebo, 1 sachet daily for 12 weeks. Melasma severity and skin health were evaluated at 4 visits for each participant (baseline, weeks 4, 8, and 12, respectively).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Severity of melasma scored by mMASI of the synbiotics group was 7.54 ± 0.79, 7.36 ± 0.80, 7.16 ± 0.73, and 6.98 ± 0.72 at baseline, weeks 4, 8, and 12, respectively, and 7.51 ± 0.86, 7.52 ± 0.88, 7.54 ± 0.86, and 7.54 ± 0.89 at baseline, weeks 4, 8, and 12, respectively, in the placebo group. Comparing between two groups at week 12, melasma score in the synbiotics supplement group was significantly lower than that in the placebo group (<jats:italic>P</jats:italic> = .008).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Oral synbiotics supplementation for 12 weeks improved the severity of melasma score.</jats:p></jats:sec>

<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>The spread of non‐invasive procedures for fat deposits removal has increased rapidly in recent years. In the field of esthetic medicine, high‐intensity focused electromagnetic field (HIFEM) technology has recently been introduced, as a tool for toning and strengthening muscles, which goes far beyond normal physical exercise.</jats:p></jats:sec><jats:sec><jats:title>Objective</jats:title><jats:p>The purpose of this study is to evaluate the efficacy and safety of a new device for body remodeling.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>A set of 15 patients (7 males and 8 females, BMI 24.05 ± 2.01 kg m<jats:sup>−2</jats:sup>, age 32–57) participated in this study. Patients were enrolled at Dermatos center, Montesilvano, Abruzzo, Italy. The technology used is FMS (Flat Magnetic Stimulation): 6–8 treatment sessions were performed. The sessions must be repeated twice a week, with a minimum of 2 days between each session. Treatment duration varies from 20 to 45 min, depending on patients.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>During 1‐month follow‐up after the last treatment evaluations, the results showed tonification, the strengthening of muscles, and the reduction of localized adiposity. There is a significant reduction in waist circumference (80.7 ± 4.3 cm <jats:italic>vs</jats:italic> 77.3 ± 5.6 cm, <jats:italic>p</jats:italic> &lt; 0.001). All patients showed relatively high satisfaction immediately after the last treatment.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Our data show that intense muscle activity is generated by FMS treatments, suggesting that this technology could be used as a convenient and effective muscle toning tool.</jats:p></jats:sec>

<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>The search of beauty and youth has received a lot of attention which is proved by increasing cosmetic techniques. The people prefer non‐surgical and invasive method for reduction and wrinkles treatment.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>In this study, we used Endolift laser for forehead wrinkles and frown line treatment to evaluate the clinical safety and effectiveness of this technique for reduction of forehead wrinkles and frown line. A total of 9 patients with forehead wrinkles and frown line were included in the current study. The results were investigated using biometric evaluation. Also, assessment was performed clinically and photographically, and physician's assessment and patient satisfaction responses were recorded.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>According to the biometric results, the skin thickness and elasticity significantly increase after Endolift laser treatment. According to the physician's assessment, 90% of patients displayed very much improvement after Endolift laser treatment, and according to the patient assessment, 91% of patients reported positive satisfaction response.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Treatment with Endolift laser is safe and an effective method for decrease of forehead wrinkles and frown line treatment. It offers as a non‐invasive alternative technique in compared to other invasive procedures for forehead wrinkles and frown line treatment.</jats:p></jats:sec>

<jats:title>Abstract</jats:title><jats:p>Drooping of the upper eyelid and eyebrow (ptosis) is common among people and cause the patients dissatisfaction. Various methods have been developed to treatment of the upper eyelid and eyebrow ptosis. However, the current methods focus on surgery to improve the disorder. But patients are worried about the risks of the procedure, and seeking for a non‐invasive alternative method. Therefore, non‐invasive methods with consistent efficient improvement are needed, especially for middle‐aged patients. This study was conducted of 9 patients who underwent the upper eyelid and eyebrow ptosis. Endolift laser method was used to treat the patients’ upper eyelid and eyebrow ptosis. The biometric assessment was used to evaluate the efficiency of the technique. Also the results were evaluated by 3 board‐certified dermatologists (blind). Additionally, patients’ satisfaction was evaluated at the end of the treatment. The biometric results showed that Endolift laser can increase the thickness, density, and elasticity of the skin in the eyelid area. The patient's satisfaction results showed excellent improvement in the 90% of patients. The results by the dermatologist displayed improvement in about 90% of patient. Endolift laser has been proved efficient and consistent for upper eyelid and eyebrow ptosis rejuvenation and treatment.</jats:p>

<jats:title>Abstract</jats:title><jats:sec><jats:title>Objective</jats:title><jats:p>Detect the expression of Interleukin‐6 (IL‐6) in the serum of patients with systemic sclerosis (SSc) and assess its association with clinical and laboratory features of the disease.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>The clinical data from 50 patients with SSc in the affiliated hospital of Xuzhou Medical University, China were retrospectively analyzed. The level of IL‐6 in peripheral blood of systemic sclerosis patients was compared between the different clinical phenotypes groups. Spearman correlation test was used to analyze the correlation of the IL‐6 with C‐reactive protein (CRP), erythrocyte sedimentation rate (ESR), creatinine, and cystatin C.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Interleukin‐6 increased in the disease course ≥5 years, systemic sclerosis‐Interstitial lung disease (SSc‐ILD), pulmonary arterial hypertension (PAH), gastrointestinal involvement, and cardiac involvement group compared with the group with disease course &lt;5 years, no SSc‐ILD, PAH, gastrointestinal involvement, and no cardiac involvement group. The differences were statistically significant (<jats:italic>p</jats:italic> &lt; 0.05). Correlation analysis showed that IL‐6 in the group with disease course ≥5 years had a positive correlation with ESR (Rs = 0.438, <jats:italic>p</jats:italic> = 0.022) and CRP (Rs = 0.825, P &lt; 0.001), whereas it was negatively correlated with creatinine (Rs = −0.481, <jats:italic>p</jats:italic> = 0.011). Nevertheless, when it came to disease course &lt;5 years, the figures had no statistically significant difference.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Serum IL‐6 in patients with systemic sclerosis is related to different clinical phenotypes. IL‐6 helps to diagnose various phases of diseases, monitor severities of diseases, and predict the prognosis of patients.</jats:p></jats:sec>